Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and safety of two formulations of human rotavirus (HRV) vaccine (Rotarix) in infants
2016-000598-19Phase 3Completed
- Sponsor
- GSK
- Start
- Aug 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of human rotavirus RIX4414 strain vaccine in rotaviral diarrhea (2 arms), sponsored by GSK. Primary endpoint: Serum anti-rotavirus IgA antibody concentrations. Started Aug 2016; status: completed.
02
Drugs
human rotavirus RIX4414 strain vaccine
03
Conditions
rotaviral diarrhea
Beyond the preview
Go deeper on 2016-000598-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000598-19.